Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Clinically demonstrated efficacy of Melphalan and Prednisone in MM subjects as well as the
confirmed inhibitory effect of dasatinib on several tyrosine kinase receptors and pathways
implicated in the pathophysiology of MM. Additionally, as a SRC inhibitor, dasatinib plays an
important role on bone metabolism through inhibition of osteoclast-mediated bone resorption
in vitro. Dasatinib could, thus, be beneficial on bone density of patients on study, through
blockage of osteolysis and control of bone lesions.